Researchers have discovered a set of related mutations that lead to intracranial aneurysms—weakened blood vessels in the brain that can burst at any time. The mutations all appear to act on the same biological signaling pathway, and the researchers report the first ever pharmaceutical treatment in a mouse model, which works by blocking this signal. The study was published in Science Translational Medicine.
About 5% of the population have unruptured intracranial aneurysms in blood vessels on the surface of the brain. Despite being ballooned arteries with weakened walls, intracranial aneurysms often go undetected -- until a rupture leads to deadly bleeding around the brain. Even when they are detected in advance, the only currently available treatment options involve surgery, which has its own set of risks, especially if the aneurysm is in a sensitive location. Finding other, non-surgical options is thus a high priority, and research into the origin of intracranial aneurysms has led the team to one such potential treatment.
Intracranial aneurysms actually come in two types called intracranial fusiform aneurysms (IFAs) and intracranial saccular aneurysms (ISAs ), with about 90% being the ISA variety. Previous research reported mutations in IFA arteries, but the origins of the more common ISA type remain unclear.
To address this issue, the team sequenced the entire exomes—all protein-encoding pieces of DNA— in cells that made up 65 aneurysmal arteries and 24 normal arteries. Along with subsequent deep-targeted sequencing, they found that six genes were common among IFAs and ISAs and never appeared in non-aneurysmal arteries, while 10 others appeared only in either IFAs or ISAs.
While several factors, such as age, hypertension, and alcohol consumption, increase the risk of intracranial aneurysms, project leader notes, “the unexpected finding that greater than 90% of aneurysms had mutations in a common set of 16 genes indicates that somatic mutation could be the major trigger in most cases.”
Further testing showed that mutations to all six of the genes common to IFAs and ISAs triggered the same NF-κB biological signaling pathway. The next step was to learn more about the mutations and try to block the abnormal signaling. First, they showed that mutations to one of the six genes, PDGDRB, could be traced along different layers within samples of human aneurysms.
Then, after linking the PDGDRB mutation with faster cell migration and inflammation in cultured cells, they discovered that these effects could be blocked with sunitinib, a drug that prevents the changes to PDGDRB that allow signaling.
Next, they created a mouse model of intracranial aneurysm by using an adenovirus to insert mutant PDGFRB into the basilar artery at the base of the brain. After a month, the size of the artery had doubled in diameter and become very weak. As in the cultured cells, the effect of the mutant gene was blocked when the mice were given sunitinib; their basilar arteries remained normal sized and strong.
“Establishing the first non-surgical animal model of intracranial aneurysm is in itself an achievement,” says the author, “but more importantly, we suppressed artery expansion with a drug, indicating that intracranial aneurysms can be pharmacologically treated.”
Additional research will be required to demonstrate that this kind of drug treatment is effective for human patients. But perhaps the more difficult hurdle will be detection. As the author explains, “unruptured intracranial aneurysms are usually detected by Magnetic Resonance Angiography or Computed Tomography Angiography during health checkups. If these tests are not available, then aneurysms are undetectable until they burst.”
https://www.science.org/doi/10.1126/scitranslmed.abq7721
How somatic mutations cause intracranial aneurysms
- 736 views
- Added
Latest News
Paranoia in the brain
By newseditor
Posted 16 Jun
In-vitro 3D culture of func…
By newseditor
Posted 15 Jun
Neural balance in the brain…
By newseditor
Posted 15 Jun
Antimalarial compounds reli…
By newseditor
Posted 15 Jun
3D imaging of whole human b…
By newseditor
Posted 14 Jun
Other Top Stories
Gene and mechanism responsible for chemotherapy induced cardiotoxic…
Read more
Regulating bone homeostasis!
Read more
How glioblastoma controls tumor suppressor?
Read more
High levels of ammonia in colon tumors inhibits T cell growth and r…
Read more
A cancer vaccine to simultaneously kill and prevent brain cancer
Read more
Protocols
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Development of an efficient…
By newseditor
Posted 12 Jun
A co-culture system of macr…
By newseditor
Posted 10 Jun
Analysis of 3D pathology sa…
By newseditor
Posted 08 Jun
Long-term expandable mouse…
By newseditor
Posted 07 Jun
Publications
NRG1-ErbB4 signaling in the…
By newseditor
Posted 15 Jun
HPV integration and cervica…
By newseditor
Posted 15 Jun
Cerebral tau pathology in c…
By newseditor
Posted 15 Jun
Cerebral tau pathology in c…
By newseditor
Posted 15 Jun
Synthetic biodegradable mic…
By newseditor
Posted 15 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar